晚期食管癌内科治疗的现状与展望

食管癌是一种常见的恶性肿瘤，由于起病隐匿，早期症状不典型、临床缺乏有效的早期诊断方法，大部分患者确诊时已为晚期，失去手术机会。晚期食管癌患者大多采用姑息性化疗、分子靶向治疗、免疫治疗等综合治疗。如何选择化疗药物、制订合理的治疗方案成为临床研究的热点。分子靶向药物选择性高，抗肿瘤活性强，已成为肿瘤治疗新的发展方向，但在食管癌中的疗效仍存在争议。肿瘤的免疫治疗尤其是免疫检测点阻断治疗取得了突破性进展，已成为肿瘤综合治疗的重要手段，并显示出良好的应用前景。...

Full description

Saved in:
Bibliographic Details
Published in中华肿瘤杂志 Vol. 38; no. 9; pp. 655 - 659
Main Author 王峰 樊青霞
Format Journal Article
LanguageChinese
Published 450052,郑州大学第一附属医院肿瘤科 2016
Subjects
免疫治疗
药物疗法
靶向治疗
食管肿瘤
药物疗法
靶向治疗
Targeted therapy
免疫治疗
Immunotherapy
食管肿瘤
Esophageal neoplasms
Drug therapy
Online AccessGet full text
ISSN0253-3766
DOI10.3760/cma.j.issn.0253-3766.2016.09.004

Cover

More Information
Summary:食管癌是一种常见的恶性肿瘤，由于起病隐匿，早期症状不典型、临床缺乏有效的早期诊断方法，大部分患者确诊时已为晚期，失去手术机会。晚期食管癌患者大多采用姑息性化疗、分子靶向治疗、免疫治疗等综合治疗。如何选择化疗药物、制订合理的治疗方案成为临床研究的热点。分子靶向药物选择性高，抗肿瘤活性强，已成为肿瘤治疗新的发展方向，但在食管癌中的疗效仍存在争议。肿瘤的免疫治疗尤其是免疫检测点阻断治疗取得了突破性进展，已成为肿瘤综合治疗的重要手段，并显示出良好的应用前景。
Bibliography:11-2152/R
Esophageal cancer （ EC） is one of common malignant tumors, and the incidence and mortality of EC in China rank the first place in the world. Because of the occult onset, the early atypical symptoms, and the lack of effective early diagnostic methods, most of patients are diagnosed at an advanced stage of the disease and lost the chance of surgery. Comprehensive treatment including palliative medical treatment, molecular targeted therapy, immunotherapy and so on is appropriate for these patients. How to choose the chemotherapy regimen and formulate reasonable treatment plan has become a hot spot in clinical research. Molecular targeted drugs have become a new developmental direction in cancer treatment because of their high specificity and antitumor activity, but the effects on esophageal cancer remain controversial. With the development of immune check point blockade treatment, breakthrough has been made in tumor immunotherapy, which has become an important means in cancer comprehensive treatment and
ISSN:0253-3766
DOI:10.3760/cma.j.issn.0253-3766.2016.09.004